Nut Supplementation to Mitigate Post-stroke Cognitive Decline (NUT-me)
Stroke, Dementia
About this trial
This is an interventional treatment trial for Stroke focused on measuring dementia, cognitive decline, nuts
Eligibility Criteria
Inclusion Criteria: Ischaemic stroke (first or recurrent stroke) in the last 6 months Able to attend 4 study visits over 3 months Motivation and willingness to participate in the study protocol No prior neurological or psychiatric disease, including dementia Can give informed consent and participate in cognitive testing Exclusion Criteria: be < 18 years; have allergy to nuts have premorbid modified Rankin scale (mRS)≥4, denoting no severe disability incapable of giving consent have problems with mastication that preclude nut intake have habitual consumption of tree nuts (>2 servings/wk) in the previous 2 months have habitual consumption of alpha-linolenic acid supplements (fish oil, flaxseed oil, and/or soy lecithin) have dementia or psychiatric disease do not speak English
Sites / Locations
- Department of Nutrition, Dietetics and Food - Monash UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Nut Group
Control Group
Participants will receive a supply of mixed nuts containing: 1 Brazil nut (~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.
Participants will follow the same protocol as the Nut group regarding appointments and collection of information. At the visits, they will receive dietary counselling on how to follow the Australian Dietary Guidelines